Context High platelet reactivity while receiving clopidogrel has been linked to cardiovascular
events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue …

The existence of poor biological response to clopidogrel has been shown in some patients.
Despite the increasing number of studies, this phenomenon remains difficult to quantify. We …

Background—In the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on
Thrombosis and Safety (GRAVITAS) trial, 6 months of high-dose clopidogrel did not reduce …

Background—Fractional flow reserve (FFR) is well established for patients undergoing
percutaneous coronary intervention, yet little is known about candidates for coronary artery …

Primary and secondary prevention of cardiovascular disease remain a public health priority.
Effective risk stratification of patients is a central requisite for effective preventative care and …

Platelet reactivity predicts ischemic outcomes in patients who undergo percutaneous
coronary intervention (PCI), but the correlation of heightened platelet response with …

Objectives: This study sought to validate the ability of the VerifyNow P2Y12 assay
(Accumetrics, San Diego, California) in predicting both ischemic and bleeding events after …

Objectives: This study was done to compare effects of high versus standard clopidogrel
maintenance doses on platelet inhibition, inflammation, and endothelial function in patients …

Background—Frequency-domain optical coherence tomography (FD-OCT) is easily able to
define both pre-and post-stenting features of the atherosclerotic plaque that can potentially …

Objectives: This study sought to evaluate the determinants and prognostic implications of
periprocedural myocardial injury (PMI) in successful percutaneous coronary intervention …